Researchers revive an abandoned depression drug target using structurally novel NK1 receptor inhibitors

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs such as aprepitant failed to show clear benefits, raising doubts about whether NK1R itself was a viable antidepressant target.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup